DC4U
DC4U is a life science company developing technologies that enable steering the human immune response. Their GlycoDC TM technology can either potentiate or suppress the immune system via specific targeting of dendritic cells by glycan modified antigen conjugates, aiming to develop novel therapeutics for various diseases including cancer, allergy, autoimmune diseases, and inflammatory conditions.
Industries
Nr. of Employees
small (1-50)
DC4U
Breukelen, Utrecht, The Netherlands, Europe
Products
Multiple sclerosis antigen-specific immunotherapy program (preclinical/early development)
An antigen-specific immunotherapy development program aiming to suppress autoimmune responses via glycan-modified self-antigen peptides that induce regulatory T-cells; described as an active development program.
Melanoma validation program for glycan-targeted tumor antigens (preclinical)
Validation of glycan-targeting technology using melanoma-specific antigens as a first oncology application to enhance tumor antigen-specific CD4+ and CD8+ responses.
Multiple sclerosis antigen-specific immunotherapy program (preclinical/early development)
An antigen-specific immunotherapy development program aiming to suppress autoimmune responses via glycan-modified self-antigen peptides that induce regulatory T-cells; described as an active development program.
Melanoma validation program for glycan-targeted tumor antigens (preclinical)
Validation of glycan-targeting technology using melanoma-specific antigens as a first oncology application to enhance tumor antigen-specific CD4+ and CD8+ responses.
Services
Early-stage partnering and co-development
Partnering options for joint development, licensing, and co-development of glycan-targeted antigen therapeutics and modifications to existing products.
Early-stage partnering and co-development
Partnering options for joint development, licensing, and co-development of glycan-targeted antigen therapeutics and modifications to existing products.
Expertise Areas
- Dendritic cell targeting and lectin-receptor engagement
- Immunomodulatory therapeutics (tolerance induction and immune activation)
- Therapeutic vaccine development (cancer and prophylactic)
- Allergy immunotherapy and food allergy products
Key Technologies
- Glycan-modified antigen conjugation
- Multivalent glyco-peptide constructs
- Nanoparticle and glycoliposome formulations
- Lectin receptor targeting (C-type lectin receptors / DC-SIGN)